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INTRODUCTION
Atypical hemolytic uremic syndrome (aHUS) is a rare throm-
botic microangiopathy characterized by overactivation 
of the alternative complement pathway. This syndrome is 
associated with severe clinical manifestations, a tendency to 
recur, and, until recently, a poor long-term prognosis (Noris 
& Remuzzi, 2009). With conventional supportive therapy, 
the expected rate of graft failure after kidney transplanta-
tion due to recurrent aHUS among patients with a muta-
tion in a complement gene ranges from 50% to 80% within 
the first five years post transplant (Le Quintrec et al., 2013; 
Zimmerhackl, Scheiring, Prufer, Taylor, & Loirat, 2007).
Eculizumab is a high-affinity humanized recombinant IgG2/
IgG4 monoclonal antibody against the complement com-
ponent 5 (C5). This medication has recently emerged as a 
promising agent for the treatment of alternative comple-
ment pathway activation disorders. In 2011, the Food and 
Drug Administration approved eculizumab for use in pedi-
atric patients with aHUS. However, experience using ecu-
lizumab in pediatric kidney transplantation remains limited 
(Barnett et al., 2013; Krid et al., 2012; Nester et al., 2011; 
Weitz, Amon, Bassler, Koenigsrainer, & Nadalin, 2011; 
Zuber, Le Quintrec, et al., 2012). Particularly little is known 
about the preemptive use of this agent in initial living-donor 
kidney transplantation in pediatric recipients with aHUS.
CASE
At age 5, the patient presented to the emergency depart-
ment with complaints of fatigue, muscle weakness, pallor, 
and vomiting without diarrhea. His blood pressure was 
elevated and laboratory data showed serum creatinine 
135.2 µmol/L (1.53 mg/dL), hemoglobin 4.50 g/dL, white 
blood cell count 15.7 x 109/L, platelet count 76 x 109/L, and 
reticulocyte count 15.8%. A peripheral blood smear showed 
schistocytes, helmet cells, and reticulocytes. Serum comple-
ment C3 level was decreased. 
The patient was diagnosed with aHUS, was treated initially 
with plasma infusions, and was then treated with plasma-
pheresis. However, the patient’s renal function deteriorated, 
and by age 6 the patient required chronic hemodialysis via 
an arteriovenous fistula. A kidney biopsy performed at that 
time showed vascular changes consistent with thrombotic 
microangiopathy and hypertension. Factor H analyses were 
performed at the Mario Negri Institute for Pharmacological 
Research in Bergamo, Italy. Sequencing of short consen-
sus repeat (SCR) 20, a mutation hot-spot region of the fac-
tor H gene, revealed no mutations. Other SCRs were then 
sequenced, and a heterozygous mutation in SCR 15 was 
found (SCR 15: c.2831T>C, p. Trp920Arg). This mutation 
has not been previously reported and its pathogenicity has 
not yet been proven. Serum complement profile at the time 
of genetic analysis showed normal levels of factor H (512.82 
mg/dL, normal range 350–750 mg/dL), C3 (126 mg/dL), and 
C4 (35 mg/dL). Other major genes associated with aHUS 
were analyzed, including complement factor I, membrane 
cofactor protein, complement factor B, and thrombomodu-
lin, and no mutations were found. The ADAMTS13 level was 
normal at 37%, and no anti-ADAMTS13 antibodies were 
identified.
The patient remained on chronic hemodialysis in combi-
nation with plasma therapy, but he continued to exhibit 
severe hypertension and had two episodes of seizures and 
encephalopathy. Although the MRI findings were consis-
tent with posterior reversible encephalopathy syndrome, a 
thromboembolic etiology of the encephalopathy was not 
completely excluded. In addition, the patient had an epi-
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Eculizumab is an anti-complement C5 monoclonal anti-
body that has recently been reported as an effective 
therapy for atypical hemolytic uremic syndrome. However, 
few data are available on the preemptive use of this medi-
cation in pediatric kidney transplantation. This report 
describes a successful preemptive use of eculizumab in 
combination with living unrelated kidney transplanta-
tion in a 10-year-old child with end-stage renal disease 
secondary to atypical hemolytic uremic syndrome who 
has a complement factor H mutation that has not been 
previously reported. Further observations and clinical tri-
als are required to address the challenges and areas of 
uncertainty related to preemptive eculizumab therapy for 
kidney transplantation in children and adults with atypical 
hemolytic uremic syndrome.
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sode of pulmonary edema without signs of fluid overload. 
The echocardiogram showed left-ventricle dilatation and 
hypertrophy with diminished systolic function and moder-
ate mitral regurgitation. Of note, the serum troponin level 
was elevated at 1.85 µg/L (N<0.08 µg/L). The patient was 
placed on the deceased-donor waiting list for a combined 
liver-kidney transplant at his home institution. However, no 
suitable donor became available.
At age 10, the patient was referred to our institution for eval-
uation for a living-donor kidney transplant. At that time, his 
height was 126 cm and estimated dry weight was 24.5 kg, 
both below the 1st percentile for his age (Z-scores -1.81 and 
-1.85, respectively) despite nutritional support and recom-
binant growth hormone therapy. The patient was deemed 
eligible for a nonrelated living-donor kidney transplant with 
the preemptive use of eculizumab. Prior to transplantation, 
the patient was fully immunized, including with the menin-
gococcal vaccine.
The University of Iowa protocol (Nester et al., 2011) was fol-
lowed for the administration of eculizumab. On days -7 and 
-1 prior to the transplantation, the patient received plasma-
pheresis with 1.5 volumes of fresh frozen plasma. This was 
followed by eculizumab, 600 mg. (induction dose for body 
weight between 20 kg and 30 kg), diluted to a concentra-
tion of 5 mg/ml, over 35 minutes. The patient tolerated 
both therapies well. Laboratory assessment of the patient’s 
complement system before and after treatment with eculi-
zumab is shown in Table 1.
Nonrelated living-donor kidney transplantation was per-
formed without perioperative complications. The donor 
was a 23-year-old male who was T- and B-cell compatible 
with the recipient. The donor was a 5 antigen mismatch 
to the recipient. The recipient’s panel reactive antibod-
ies were 0% and there were no donor-specific antibodies. 
Induction immunosuppression consisted of thymoglobulin 
and methylprednisolone. Triple maintenance immunosup-
pression included tacrolimus, mycophenolate mofetil, and 
prednisone. The patient had urine output immediately after 
the operation and by post-transplant day 2, the serum cre-
Table 1 | Parameters of complement system and related laboratory values prior to eculizumab administration. Data shown for 
the initial seven doses.
C5 Functional 
Assay
AH50 CH50 C3 C4 LDH
Hapto-
globin
Hemoglobin
Normal range / units 137–37900 U/ml 75–170% 31–60 U/ml
70–245 
mg/dL
 16–56 
mg/dL
120–325 
U/L
25–200
mg/dL 10.9-13.3 g/dL 
Pre transplant*
Dose 1 (day -7) 17638 98 44 74 20 245 47 9.5
Dose 2 (day -1) <10 <10 <10 65 20 140 106 9.1
Post transplant
day +1 <10 <10 <10 58 12 226 95 7.3
Dose 3 (day +7) — <10 <10 109 23 270 — 7.2
Dose 4 (day +14) <10 <10 <10 — — 201 194 9.1
Dose 5 — <10 <10 137 26 213 146 11.7
Dose 6 <10 <10 <10 131 22 — 93 12.1
Dose 7 <10 <10 <10 127 50 — 96 12.5
* Laboratory test samples were drawn before plasma therapy and before eculizumab.
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atinine was 53.04 µmol/L (0.6 mg/dL). The patient received 
two weekly doses of eculizumab, and thereafter was placed 
on an every-other-week maintenance regimen. We observed 
an initial decrease in the serum complement C3 level after 
the first dose of eculizumab, which persisted in the immedi-
ate post-transplant period but normalized about one month 
after transplantation (Table 1). Plasma therapies were not 
used during or after transplantation.
Two months after transplantation, the patient returned to his 
home institution, where he continues to receive eculizumab 
infusions every other week. At nine months’ follow-up, his 
renal function remained stable, and there was no clinical or 
biochemical evidence of aHUS recurrence.
DISCUSSION
Until recently, there were few therapeutic options in the 
treatment of children with end-stage renal disease (ESRD) 
secondary to aHUS. In most cases, treatment was limited to 
chronic dialysis. Isolated kidney transplantation has a high 
rate of recurrence, and combined liver-kidney transplanta-
tion, while potentially curative for the underlying genetic 
defect, poses a high risk for mortality. Most children with 
aHUS and ESRD require, in addition to dialysis, chronic 
plasma therapy to prevent extrarenal manifestations of 
aHUS. In the case of our patient, his extrarenal complica-
tions could have been explained by alternative comple-
ment pathway activation. This included two occurrences of 
encephalopathy and the episode of severe ventricular dys-
function in combination with respiratory insufficiency.
A number of pathogenic mutations in the SCR 15 region 
of the complement factor H gene have been identified 
(Bresin et al., 2013). However, to our knowledge, the muta-
tion found in our patient (SCR 15: c.2831T>C) has not been 
previously reported, and its pathogenicity has not yet been 
demonstrated. In view of his normal factor H level, it does 
not appear that the mutation in our patient is associated 
with a quantitative factor H deficiency, and therefore a func-
tional defect may be expected; however, a functional analy-
sis of factor H has not been performed. 
Donor selection is a challenge for children with aHUS and 
ESRD. Living related donation is usually not an option due 
to a high level of pathogenic genes encoding alternative 
complement pathway components carried in the families of 
these patients. In our case, we did not offer genetic test-
ing to the family members because of financial consider-
ations and because a negative test result cannot exclude 
the possibility of another causative genetic defect either not 
yet discovered or not covered by testing. Therefore, genetic 
testing is not capable of identifying relatives as suitable can-
didates for kidney donation. Adverse outcomes for both the 
recipient and the donor after kidney donation by a family 
member to a child with aHUS have been described (Donne 
et al., 2002).
Despite promising reports, many questions regarding the 
preemptive use of eculizumab in renal transplantation 
remain unanswered. These include the utility of pretrans-
plant plasmapharesis, optimization of the eculizumab dos-
age before and after transplantation, treatment regimens 
for deceased versus nonrelated living-donor transplants, 
the optimal induction and maintenance of immunosuppres-
sion, laboratory criteria for complement blockage under 
eculizumab, and the length and cost of the treatment with 
this agent.
In our case, we used preemptive plasmapheresis before 
eculizumab infusions as per the University of Iowa protocol 
(Nester et al., 2011). However, other investigators suggest 
that eculizumab without plasma therapy may be sufficient 
to prevent aHUS recurrence (Krid et al., 2012; Roman-Ortiz 
et al., 2014; Weitz et al., 2011). We used eculizumab on 
days -7 and -1 prior to the transplantation. But even after 
the first dose of eculizumab, the functional activity of the 
terminal complement components was fully suppressed 
(Table 1). This is consistent with data indicating that comple-
ment blockade is complete as soon as one hour after the 
first eculizumab infusion. Effective treatment with a single 
dose of eculizumab before surgery has been reported (Krid 
et al., 2012; Roman-Ortiz et al., 2014). Administration of 
eculizumab within the first 24 hours after surgery is cur-
rently recommended due to possible complement activa-
tion after kidney reperfusion and surgical trauma. Disease 
exacerbation in the immediate postoperative period has 
been documented when eculizumab was not administered 
within the first day post transplant (Ranch, Crowther, Arar, 
& Assanasen, 2014). Blockade of the alternative pathway 
above the C5 step is not expected after eculizumab treat-
ment. Additionally, similar changes in C3 levels observed 
in our patient after eculizumab treatment have also been 
reported in other pediatric cases (Nester et al., 2011; Weitz 
et al., 2011); however, they are not well understood. Finally, 
we chose thymoglobulin for induction immunosuppression, 
but successful use of basiliximab in patients with aHUS has 
also been described (Nester et al., 2011; Roman-Ortiz et al., 
2014).
The advantages of eculizumab over previously available 
standards of care are obvious. The use of this agent reduces 
central line-related complications associated with plas-
mapharesis. Additionally, eculizumab improves renal survival, 
thus reducing kidney transplantation failure due to aHUS 
recurrence and preventing the need for chronic dialysis. 
Together, the benefits of eculizumab treatment contribute to 
improved quality of life and allow parents and children to 
go about their lives. However, the financial burden associ-
ated with maintenance eculizumab therapy is an important 
issue, especially in resource-limited countries. Depending 
on the size of the child, the annual cost of standard main-
tenance treatment may vary from around $100,000 to more 
than $500,000, making eculizumab one of the most expen-
sive lifelong medical treatments (Zuber, Le Quintrec, et al., 
2012). This and other concerns prompted some to consider 
the possibility of discontinuing eculizumab therapy with strict 
home monitoring for early signs of relapse in patients with 
aHUS who achieve stable remission (Ardissino et al., 2014).
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Eculizumab appears to be an effective agent for preemp-
tive therapy in nonrelated living-donor kidney transplanta-
tion in patients with aHUS. However, current protocols for 
the prophylactic use of eculizumab in renal transplantation 
are empirical. More observations are required to develop 
the most effective and cost-efficient approach to the use of 
this agent. Incorporating cases of this kind into the national 
registry may help optimize treatment strategies.
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